By
Drug Target Review2025-10-03T09:21:07
Researchers have developed a new blood test method, CloneSeq-SV, that tracks treatment-resistant ovarian cancer cells over time. The approach could help predict recurrence and guide targeted therapies.
Already a member? Sign in
By highlighting cutting-edge research and its practical applications, Drug Target Review enables readers to make decisions that accelerate innovation, translate discoveries into therapies, and create tangible benefits for patients worldwide.
By becoming a member you join a connected and collaborative community driving the industry forward. Member benefits include:
2023-12-11T10:49:07
Sponsored by Leica Microsystems
2024-02-01T12:06:43
Sponsored by Leica Microsystems
2023-03-02T13:57:58
Sponsored by Cell Signaling Technology
2026-06-24T13:00:00 2026-06-24T14:00:00
Sponsored by HUB Organoids
2025-04-22T14:58:00
Sponsored by Takara Bio USA
2024-01-10T08:23:16
Sponsored by BellBrook Labs
Site powered by Webvision Cloud